Adel Gouri, Aoulia Dekaken, Mohamed Chefrour, Arifa Aissaoui, Nihad Labed, Wissem Abdaoui and Sadek Benharkat
For decades, relevant improvements in cancer therapy have occurred, with a significant increase in the overall survival of patients. Nevertheless, with the recent emergence of highly selective molecular targeted agents and high-throughput genomic characterization technologies, robust and well-validated cancer biomarkers are increasingly needed.
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi